Would love your comments on the phase 2b trials Mozz and team
I did notice the placebo group had a 43% reduction in pain vs 55% for the LOR group. About a 10% difference...I'm trying to remember what our separation was like?
Even if this is a great drug there will still be many questions. The phase 3 is not blinded, where can it be marketed. What would they have to do to satisfy FDA and EMA or would it just be licenced off and sold privately.
In that case is it really competition? There is of course space for more than 1 drug in this huge market. Could it be an adjunct therapy? It would be nice though if paradigm becomes the first DMOAD!
PAR Price at posting:
$2.31 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)